risperidone has been researched along with Anochlesia in 46 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in dopaminergic development." | 3.77 | Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. ( Aizawa, M; Iwakura, Y; Mizuno, M; Namba, H; Nawa, H; Shcherbakova, K; Sotoyama, H; Wang, R; Zheng, Y, 2011) |
| "Risperidone treatment also led to a decrease in Akt and CREB phosphorylation in the prefrontal cortex." | 1.56 | Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats. ( Bartlett, MG; Callahan, PM; Hernandez, CM; Pillai, A; Poddar, I; Terry, AV; Yang, X, 2020) |
| "We also examined them on catalepsy as extrapyramidal side effects and novel object recognition test in cognitive functions in rats." | 1.56 | Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats. ( Arakawa, K; Maehara, S, 2020) |
| "Co-treatment with risperidone and escitalopram (5mg/kg) or mirtazapine (10mg/kg) more efficiently increased the release of 5-HT but not DA in the rat frontal cortex, as compared to drugs given alone." | 1.48 | The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex. ( Górska, A; Gołembiowska, K; Kamińska, K; Noworyta-Sokołowska, K; Rogóż, Z; Wojtas, A, 2018) |
| "9j exhibited a low potential for catalepsy, consistent with results with risperidone." | 1.43 | Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics. ( Chen, XW; Fu, L; Li, JQ; Sun, YY, 2016) |
| " The objective of this study was to use pharmacokinetic and pharmacodynamic modeling tools to relate CAT with D2RO in rats and to compare that with the relationship between D2RO and EPS in humans." | 1.40 | Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach. ( Barton, HA; Danhof, M; de Greef, R; Grimwood, S; Groothuis, GM; Johnson, M; Kozielska, M; Pilla Reddy, V; Proost, JH; Vermeulen, A, 2014) |
| " Preliminary tests for oral bioavailability also revealed promising results for this new class of potential antipsychotic compounds." | 1.38 | Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments. ( Enzensperger, C; Fleck, C; Lehmann, J; Mueller, FK; Robaa, D; Schulze, M; Siol, O, 2012) |
| "The drug-induced catalepsy was strongly attenuated, but not abolished, in M(4) knockout mice as compared to wild-type controls." | 1.37 | Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. ( Dencker, D; Fink-Jensen, A; Schmidt, LS; Schülein, C; Wess, J; Woldbye, DP; Wörtwein, G, 2011) |
| "Risperidone has lower affinity for alpha2-adrenoceptors than clozapine but higher than most other APDs." | 1.36 | Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. ( Frånberg, O; Jardemark, K; Konradsson-Geuken, A; Langlois, X; Marcus, MM; Svensson, TH; Wiker, C, 2010) |
| "ACP-103 also attenuated catalepsy produced by haloperidol or risperidone." | 1.34 | ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. ( Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I, 2007) |
| "Because catalepsy is thought to be a good predictor of extrapyramidal symptoms in humans, treatment with orexin-1 antagonists might decrease the occurrence or severity of antipsychotic treatment-emergent extrapyramidal symptoms in humans." | 1.34 | The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. ( Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK, 2007) |
| "Haloperidol and risperidone induced catalepsy at doses producing >80% D2RO, while aripiprazole despite higher D2RO (>90%) induced no catalepsy." | 1.33 | Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. ( Fletcher, PJ; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE, 2006) |
| "Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms." | 1.32 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. ( Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S, 2004) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Aripiprazole did not inhibit physostigmine- or norepinephrine-induced lethality in rats." | 1.32 | Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. ( Altar, CA; Burris, KD; Hirose, T; Kikuchi, T; Kitagawa, H; Miwa, T; Nabeshima, T; Uwahodo, Y; Yamada, S, 2004) |
| "Induction of catalepsy and inhibition of stereotypies weaker than standards, along with a lower increase in serum prolactin levels, were indicative of a potential atypical profile for this compound." | 1.30 | 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). ( Agut, J; Anglada, L; Bolós, J; De la Fuente, N; Gubert, S; Ortiz, JA; Planas, JM; Príncep, M; Sacristán, A, 1998) |
| "The score of catalepsy was significantly low 120 min after administration of RIS as compared to HPD." | 1.29 | [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol]. ( Hayakawa, H; Kawai, K; Kikumoto, O; Motohashi, N; Okamoto, Y; Yamawaki, S; Yokota, N, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (26.09) | 18.2507 |
| 2000's | 15 (32.61) | 29.6817 |
| 2010's | 17 (36.96) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Hrib, NJ | 1 |
| Jurcak, JG | 1 |
| Huger, FP | 1 |
| Errico, CL | 1 |
| Dunn, RW | 2 |
| Millan, MJ | 1 |
| Peglion, JL | 1 |
| Vian, J | 1 |
| Rivet, JM | 1 |
| Brocco, M | 1 |
| Gobert, A | 1 |
| Newman-Tancredi, A | 2 |
| Dacquet, C | 1 |
| Bervoets, K | 1 |
| Girardon, S | 1 |
| Howard, HR | 1 |
| Lowe, JA | 1 |
| Seeger, TF | 1 |
| Seymour, PA | 1 |
| Zorn, SH | 1 |
| Maloney, PR | 1 |
| Ewing, FE | 1 |
| Newman, ME | 1 |
| Schmidt, AW | 1 |
| Furman, JS | 1 |
| Robinson, GL | 1 |
| Jackson, E | 1 |
| Johnson, C | 1 |
| Morrone, J | 1 |
| Bolós, J | 2 |
| Gubert, S | 2 |
| Anglada, L | 2 |
| Planas, JM | 2 |
| Burgarolas, C | 1 |
| Castelló, JM | 1 |
| Sacristán, A | 2 |
| Ortiz, JA | 2 |
| Reitz, AB | 1 |
| Baxter, EW | 1 |
| Codd, EE | 1 |
| Davis, CB | 1 |
| Jordan, AD | 1 |
| Maryanoff, BE | 1 |
| Maryanoff, CA | 1 |
| McDonnell, ME | 1 |
| Powell, ET | 1 |
| Renzi, MJ | 1 |
| Schott, MR | 1 |
| Scott, MK | 1 |
| Shank, RP | 1 |
| Vaught, JL | 1 |
| Agut, J | 1 |
| Príncep, M | 1 |
| De la Fuente, N | 1 |
| Raviña, E | 2 |
| Negreira, J | 1 |
| Cid, J | 1 |
| Masaguer, CF | 2 |
| Rosa, E | 1 |
| Rivas, ME | 2 |
| Fontenla, JA | 2 |
| Loza, MI | 2 |
| Tristán, H | 1 |
| Cadavid, MI | 2 |
| Sanz, F | 1 |
| Lozoya, E | 1 |
| Carotti, A | 1 |
| Carrieri, A | 1 |
| Birch, AM | 1 |
| Bradley, PA | 1 |
| Gill, JC | 1 |
| Kerrigan, F | 1 |
| Needham, PL | 1 |
| Casariego, I | 1 |
| Montenegro, GY | 1 |
| Enguix, MJ | 1 |
| Villazon, M | 1 |
| Demontis, GC | 1 |
| Kołaczkowski, M | 1 |
| Marcinkowska, M | 2 |
| Bucki, A | 1 |
| Pawłowski, M | 1 |
| Mitka, K | 1 |
| Jaśkowska, J | 1 |
| Kowalski, P | 1 |
| Kazek, G | 1 |
| Siwek, A | 1 |
| Wasik, A | 1 |
| Wesołowska, A | 1 |
| Mierzejewski, P | 2 |
| Bienkowski, P | 2 |
| Chen, XW | 1 |
| Sun, YY | 1 |
| Fu, L | 1 |
| Li, JQ | 1 |
| Xiamuxi, H | 1 |
| Wang, Z | 1 |
| Li, J | 1 |
| Wang, Y | 1 |
| Wu, C | 1 |
| Yang, F | 1 |
| Jiang, X | 1 |
| Liu, Y | 1 |
| Zhao, Q | 1 |
| Chen, W | 1 |
| Zhang, J | 1 |
| Xie, Y | 1 |
| Hu, T | 1 |
| Xu, M | 1 |
| Guo, S | 1 |
| Akber Aisa, H | 1 |
| He, Y | 1 |
| Shen, J | 1 |
| Poddar, I | 1 |
| Callahan, PM | 1 |
| Hernandez, CM | 1 |
| Pillai, A | 1 |
| Yang, X | 1 |
| Bartlett, MG | 1 |
| Terry, AV | 1 |
| Arakawa, K | 1 |
| Maehara, S | 1 |
| Moe, AAK | 1 |
| Medely, GA | 1 |
| Reeks, T | 1 |
| Burne, THJ | 1 |
| Eyles, DW | 1 |
| Zergiebel, S | 1 |
| Fleck, C | 2 |
| Arndt, HD | 1 |
| Enzensperger, C | 2 |
| Seeling, A | 1 |
| Kamińska, K | 1 |
| Górska, A | 1 |
| Noworyta-Sokołowska, K | 1 |
| Wojtas, A | 1 |
| Rogóż, Z | 1 |
| Gołembiowska, K | 1 |
| Qureshi, M | 1 |
| Aqil, M | 1 |
| Imam, SS | 1 |
| Ahad, A | 1 |
| Sultana, Y | 1 |
| Johnson, M | 1 |
| Kozielska, M | 1 |
| Pilla Reddy, V | 1 |
| Vermeulen, A | 1 |
| Barton, HA | 1 |
| Grimwood, S | 1 |
| de Greef, R | 1 |
| Groothuis, GM | 1 |
| Danhof, M | 1 |
| Proost, JH | 1 |
| Kolaczkowski, M | 1 |
| Wesolowska, A | 1 |
| Samochowiec, J | 1 |
| Pawlowski, M | 1 |
| Auclair, AL | 1 |
| Kleven, MS | 1 |
| Barret-Grévoz, C | 1 |
| Barreto, M | 1 |
| Depoortère, R | 1 |
| Muthu, MS | 1 |
| Rawat, MK | 1 |
| Mishra, A | 1 |
| Singh, S | 1 |
| Marchese, G | 2 |
| Casu, G | 1 |
| Casti, P | 2 |
| Spada, GP | 1 |
| Pani, L | 2 |
| Pacchioni, AM | 1 |
| Gabriele, A | 1 |
| Donovan, JL | 1 |
| DeVane, CL | 1 |
| See, RE | 1 |
| Marcus, MM | 2 |
| Wiker, C | 1 |
| Frånberg, O | 1 |
| Konradsson-Geuken, A | 1 |
| Langlois, X | 1 |
| Jardemark, K | 2 |
| Svensson, TH | 2 |
| Wadenberg, ML | 1 |
| Fjällström, AK | 1 |
| Federley, M | 1 |
| Persson, P | 1 |
| Stenqvist, P | 1 |
| Fink-Jensen, A | 1 |
| Schmidt, LS | 1 |
| Dencker, D | 1 |
| Schülein, C | 1 |
| Wess, J | 1 |
| Wörtwein, G | 1 |
| Woldbye, DP | 1 |
| Krishnamurthy, S | 1 |
| Garabadu, D | 1 |
| Reddy, NR | 1 |
| Joy, KP | 1 |
| Sotoyama, H | 1 |
| Zheng, Y | 1 |
| Iwakura, Y | 1 |
| Mizuno, M | 1 |
| Aizawa, M | 1 |
| Shcherbakova, K | 1 |
| Wang, R | 1 |
| Namba, H | 1 |
| Nawa, H | 1 |
| Malmerfelt, A | 1 |
| Shahid, M | 1 |
| Schulze, M | 1 |
| Siol, O | 1 |
| Robaa, D | 1 |
| Mueller, FK | 1 |
| Lehmann, J | 1 |
| Funakoshi, T | 2 |
| Chaki, S | 2 |
| Kawashima, N | 2 |
| Suzuki, Y | 2 |
| Yoshikawa, R | 1 |
| Kumagai, T | 2 |
| Nakazato, A | 2 |
| Kameo, K | 1 |
| Goto, M | 1 |
| Okuyama, S | 2 |
| Ogawa, S | 1 |
| Komurasaki, T | 1 |
| Nakai, S | 1 |
| Hirose, T | 2 |
| Uwahodo, Y | 2 |
| Imaoka, T | 1 |
| Okazaki, H | 1 |
| Miwa, T | 3 |
| Nakai, M | 1 |
| Yamada, S | 2 |
| Dunn, B | 1 |
| Burris, KD | 2 |
| Molinoff, PB | 1 |
| Tottori, K | 1 |
| Altar, CA | 2 |
| Kikuchi, T | 2 |
| Bartholini, F | 1 |
| Casu, MA | 1 |
| Ruiu, S | 1 |
| Congeddu, E | 1 |
| Tambaro, S | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Kitagawa, H | 1 |
| Nabeshima, T | 1 |
| Natesan, S | 1 |
| Reckless, GE | 1 |
| Nobrega, JN | 1 |
| Fletcher, PJ | 1 |
| Kapur, S | 1 |
| Gardell, LR | 1 |
| Vanover, KE | 1 |
| Pounds, L | 1 |
| Johnson, RW | 1 |
| Barido, R | 1 |
| Anderson, GT | 1 |
| Veinbergs, I | 1 |
| Dyssegaard, A | 1 |
| Brunmark, P | 1 |
| Tabatabaei, A | 1 |
| Davis, RE | 1 |
| Brann, MR | 1 |
| Hacksell, U | 1 |
| Bonhaus, DW | 1 |
| Rasmussen, K | 1 |
| Hsu, MA | 1 |
| Noone, S | 1 |
| Johnson, BG | 1 |
| Thompson, LK | 1 |
| Hemrick-Luecke, SK | 1 |
| Corbett, R | 1 |
| Hartman, H | 1 |
| Kerman, LL | 1 |
| Woods, AT | 1 |
| Strupczewski, JT | 1 |
| Helsley, GC | 1 |
| Conway, PC | 1 |
| Kikumoto, O | 1 |
| Okamoto, Y | 1 |
| Hayakawa, H | 1 |
| Yokota, N | 1 |
| Kawai, K | 1 |
| Motohashi, N | 1 |
| Yamawaki, S | 1 |
| Takahashi, S | 1 |
| Sonehara, K | 1 |
| Takagi, K | 1 |
| Horikomi, K | 1 |
| Mita, N | 1 |
| Nagase, H | 1 |
| Iizuka, K | 1 |
| Sakai, K | 1 |
| Ninan, I | 1 |
| Kulkarni, SK | 1 |
| Rodríguez-Arias, M | 1 |
| Broseta, I | 1 |
| Aguilar, MA | 1 |
| Miñarro, J | 1 |
| Pouzet, B | 1 |
| Didriksen, M | 1 |
| Arnt, J | 1 |
46 other studies available for risperidone and Anochlesia
| Article | Year |
|---|---|
Synthesis and biological evaluation of a series of substituted N-alkoxyimides and -amides as potential atypical antipsychotic agents.
Topics: Amides; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Catalepsy; Chemical Phenomen | 1991 |
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin
Topics: 2-Naphthylamine; Animals; Body Temperature Regulation; Catalepsy; CHO Cells; Cricetinae; Dopamine An | 1995 |
3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Brain; Catalepsy; Cloza | 1996 |
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Biological Avail | 1996 |
Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Cerebral Cortex; Co | 1998 |
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).
Topics: Administration, Oral; Animals; Antipsychotic Agents; Brain; Catalepsy; Cell Line; Chromones; Drug Ev | 1998 |
Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical an
Topics: Animals; Antipsychotic Agents; Aorta, Thoracic; Brain; Catalepsy; Cattle; Dopamine Agents; In Vitro | 1999 |
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dioxanes; Dopamine Antagonists; Drug Evaluation, Pr | 1999 |
Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Butyrophenones; Catalepsy; Ca | 2000 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; C | 2014 |
Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Cognition; Locomotion; Male; Pip | 2016 |
Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dogs; Half-Life; | 2017 |
Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Brain-Derived Neurotrophic Fa | 2020 |
Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2020 |
Short- and long-term effects of risperidone on catalepsy sensitisation and acquisition of conditioned avoidance response: Adolescent vs adult rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Biogenic Monoamines; Brain; Catalepsy; Corticosterone; D | 2017 |
Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Dose-Response Relationship, Drug; Este | 2017 |
The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex.
Topics: Animals; Antidepressive Agents; Catalepsy; Citalopram; Dopamine; Drug Synergism; Frontal Lobe; Locom | 2018 |
Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study.
Topics: Administration, Intranasal; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Catalepsy; Chito | 2019 |
Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Catalepsy; Computer Simulation; Dopamine D2 R | 2014 |
Antipsychotic-like effects of zolpidem in Wistar rats.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Catalepsy; Diazepam; Dose-Response Rel | 2016 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Ben | 2009 |
PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Drug Compounding; Lactic Acid; Mice; Microscopy, | 2009 |
Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Chemistry, Pharmaceutical; | 2009 |
P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Catalepsy; Corpus Striatum; Cyclos | 2010 |
Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Antipsychotic Agents; Avoidance Learning; Cataleps | 2010 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagoni | 2011 |
Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.
Topics: Animals; Antipsychotic Agents; Breeding; Catalepsy; Haloperidol; Male; Mice; Motor Activity; Recepto | 2011 |
Risperidone in ultra low dose protects against stress in the rodent cold restraint model by modulating stress pathways.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain; Catalepsy; Cold Temperature; Corticosterone; | 2011 |
Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Biomarkers; Catalepsy; Dis | 2011 |
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Avoidance L | 2012 |
Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Biological Availability; Calciu | 2012 |
In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Central Nervous System Stimulants; Cloza | 2002 |
In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Blood Pressure; Catalepsy; Do | 2002 |
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Corpus Striatum; Dopam | 2003 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blepharoptosis; Catalepsy; Dihydroxyph | 2004 |
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Catalepsy; Dopamine Antagonists; Do | 2006 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalep | 2007 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazol | 2007 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Ca | 1993 |
[Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; gamma-Aminobutyric Acid; Haloperidol; Iso | 1993 |
Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Agonists; Free Radical | 1999 |
Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Benzodiazepines; Catalepsy; C | 1999 |
Lack of specific effects of selective D(1) and D(2) dopamine antagonists vs. risperidone on morphine-induced hyperactivity.
Topics: Animals; Benzazepines; Catalepsy; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Male; Mice | 2000 |
Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.
Topics: Animals; Antipsychotic Agents; Catalepsy; Central Nervous System Stimulants; Dextroamphetamine; Dose | 2002 |